How We Got Here
Understanding the CR extension in context requires understanding the path of hemp regulation since 2018. It's a story of rapid market development outpacing regulatory frameworks built for a different vision of the industry.
2018: The Farm Bill Legalizes Hemp
The Agricultural Improvement Act of 2018 removed hemp, defined as cannabis with 0.3% or less Delta-9 THC on a dry weight basis, from the Controlled Substances Act's definition of marijuana. This legalized hemp cultivation, processing, and sale at the federal level, with states given authority to regulate hemp programs within federal guidelines.
The bill's primary framing was agricultural: a new commodity crop with fiber, grain, and CBD wellness applications. The intoxicating cannabinoid market that would later develop was not the bill's central focus.
2019-2021: Market Development and the CBD Boom
Following legalization, the CBD market grew rapidly, driven by wellness and consumer product applications. FDA began grappling with questions about CBD's status as a food and supplement ingredient, issuing warning letters over unsubstantiated health claims while never fully resolving the underlying regulatory questions.
During this period, extraction and processing innovation began exploring cannabinoid conversion possibilities beyond CBD isolation, laying groundwork for what would become the Delta-8 THC market.
2021-2023: The Delta-8 Boom and Regulatory Response
Delta-8 THC products, converted from hemp-derived CBD, exploded in popularity as a legal, widely available intoxicating alternative to marijuana in states where cannabis remained illegal. This growth outpaced any specific federal regulatory framework designed for it, since the 2018 bill hadn't anticipated this market development.
States began responding independently: some banned Delta-8 explicitly, others restricted it, and many took no action, creating the state-by-state patchwork that persists today. DEA's position on Delta-8's legal status remained genuinely ambiguous, without definitive federal resolution.
2023-2025: Growing Pressure for a Federal Response
As the intoxicating hemp product market (Delta-8, Delta-9 hemp products, HHC) continued growing, pressure built for a more defined federal regulatory response. Farm Bill reauthorization negotiations, which should have concluded around 2023, became a venue for competing visions of hemp's regulatory future: tighter restriction on intoxicating cannabinoids versus continued protection of the market that had developed.
This period saw the Farm Bill repeatedly extended without resolution, as the hemp regulatory question became one of several sticking points in broader agricultural policy negotiations.
2026: The November 12 Deadline and the CR Extension
A more restrictive regulatory framework was set to take effect on November 12, 2026, including total THC testing requirements, DEA-registered laboratory mandates, and stricter serving limits that would have eliminated much of the current intoxicating hemp product market.
Sustained industry advocacy, described in detail elsewhere in this publication, led to a Continuing Resolution rider that blocked the November 12 framework and extended current hemp status through December 11, 2026, buying additional time for a permanent legislative resolution.
What This History Suggests About What Comes Next
The pattern since 2018 has been consistent: market development outpacing regulatory frameworks, followed by contested attempts to catch regulation up to market reality. The permanent framework that eventually emerges from Farm Bill, omnibus, or extenders negotiations will likely reflect an attempt to finally resolve this multi-year gap, one way or another.
Low Gravity Hemp has operated through every phase of this regulatory evolution with a consistent commitment to full-panel documentation and compliance. Contact us to talk through how our approach has adapted to each stage of hemp's regulatory history.
